Clinical Trials Logo

Gastrointestinal Symptoms clinical trials

View clinical trials related to Gastrointestinal Symptoms.

Filter by:

NCT ID: NCT01171014 Completed - Clinical trials for Gastrointestinal Symptoms

Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms

Start date: June 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study was to investigate the dose response effect of Bifidobacterium lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms.

NCT ID: NCT01116388 Completed - Autism Clinical Trials

A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders

GFCF
Start date: April 2010
Phase: N/A
Study type: Interventional

Doctors at MassGeneral Hospital for Children (MGHfC) are doing a research study to learn if a gluten free-dairy free (GFCF) diet is helpful in improving gastrointestinal symptoms associated with autism. Hypothesis: The gluten free/casein free diet (GFCF) will result in a higher proportion of subjects having reduction in gastrointestinal (GI) symptoms associated with autism spectrum disorders (ASD). Primary Study Objective: - To assess the effect of a GFCF diet on GI symptoms associated with ASD. Secondary Objectives: - To assess if improvements in GI symptoms result in improvements in autistic behavior when using a GFCF diet in the dietary management of GI symptoms associated with ASD - To determine the nutritional impact of a GFCF restrictive diet - To assess the role of food allergies in the manifestation of GI symptoms This is a 14-week study that requires between 5 & 9 office visits. All study related activities -including physical exams, blood samples and allergy testing - and an amino acid based supplement drink, are at no cost. Research study visits will take place at MGHfC in Boston, or at Newton Wellesley Hospital in Newton, or at Lurie Center/LADDERS in Lexington.

NCT ID: NCT00677378 Completed - Esophagitis Clinical Trials

Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain

TRPV1
Start date: December 2006
Phase: N/A
Study type: Observational

We would like to evaluate the changes in nerve innervation and TRPV1 receptor expression along with microscopic changes associated with heart burn and abdominal pain

NCT ID: NCT00574197 Completed - Clinical trials for Heart Transplantation

Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients

Start date: June 2006
Phase: Phase 4
Study type: Interventional

Mycophenolate sodium (Myfortic®) is a newly developed enteric-coated tablet version of mycophenolate mofetil (Cellcept®) which is currently used as therapy for the prevention of transplant rejection. Myfortic® was developed to improve the gastrointestinal tolerability of Cellcept®. The new enteric-coated, Myfortic® is presently FDA approved for the prevention of acute kidney rejection only. There is no clinical data of its use in heart transplant patients.